Last reviewed · How we verify

Tobramycin Powder

Washington University School of Medicine · FDA-approved active Small molecule Quality 5/100

Tobramycin Powder is a Small molecule drug developed by Washington University School of Medicine. It is currently FDA-approved. Also known as: TOBI®Podhaler.

At a glance

Generic nameTobramycin Powder
Also known asTOBI®Podhaler
SponsorWashington University School of Medicine
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tobramycin Powder

What is Tobramycin Powder?

Tobramycin Powder is a Small molecule drug developed by Washington University School of Medicine.

Who makes Tobramycin Powder?

Tobramycin Powder is developed and marketed by Washington University School of Medicine (see full Washington University School of Medicine pipeline at /company/washington-university-school-of-medicine).

Is Tobramycin Powder also known as anything else?

Tobramycin Powder is also known as TOBI®Podhaler.

What development phase is Tobramycin Powder in?

Tobramycin Powder is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing